SEARCH:   Advanced

Blood, 1 January 2007, Vol. 109, No. 1, pp. 339-342. Prepublished online as a Blood First Edition Paper on August 31, 2006; DOI 10.1182/blood-2006-03-009472. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2006-03-009472v1 109/1/339    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Xu, X. Articles by Zhao, Z. J. Search for Related Content PubMed PubMed Citation Articles by Xu, X. Articles by Zhao, Z. J. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 13, 2006 Accepted August 16, 2006 JAK2V617F: Prevalence in a large Chinese hospital population Xuesong Xu, Qi Zhang, Jian Luo, Shu Xing, Qingshan Li, Sanford B. Krantz, Xueqi Fu, and Zhizhuang J. Zhao* Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, China Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA * Corresponding author; email: joe-zhao{at}ouhsc.edu. Recently, the JAK2 V617F mutation was found in patients with myeloproliferative disorders (MPDs) including most with polycythemia vera (PV). The mutant JAK2 has increased kinase activity, and it was shown to be pathogenic in mouse models. Herein we analyzed blood samples randomly collected from a clinical laboratory. Surprisingly, as many as 37 samples out of a total of 3935 were found positive for the JAK2 mutation. However, only one of these samples had blood test results indicative for probable PV, but several had non-hematological diseases. On average, samples with the mutation had normal red cell counts but significantly higher white blood cell and platelet counts although most were within the normal range. The data suggest that the JAK2 V617F mutation is apparently much more common than MPDs. Its occurrence may be a prelude to full blood cell abnormalities and other diseases, but it cannot by itself diagnose MPDs. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: JAK2V617F and phenotype: questions galore Animesh Pardanani Blood 2007 109: 8. [Full Text] [PDF] JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis Catherine Lacout, Didier F. Pisani, Micheline Tulliez, Françoise Moreau Gachelin, William Vainchenker, and Jean-Luc Villeval Blood 2006 108: 1652-1660. [Abstract] [Full Text] [PDF] This article has been cited by other articles: M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods Am J Clin Pathol, November 1, 2009; 132(5): 713 - 721. [Abstract] [Full Text] [PDF] H. Haeno, R. L. Levine, D. G. Gilliland, and F. Michor A progenitor cell origin of myeloid malignancies PNAS, September 29, 2009; 106(39): 16616 - 16621. [Abstract] [Full Text] [PDF] F. Dentali, A. Squizzato, L. Brivio, L. Appio, L. Campiotti, M. Crowther, A. M. Grandi, and W. Ageno JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood, May 28, 2009; 113(22): 5617 - 5623. [Abstract] [Full Text] [PDF] I. Rapado, S. Grande, E. Albizua, R. Ayala, J.-A. Hernandez, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms J. Mol. Diagn., March 1, 2009; 11(2): 155 - 161. [Abstract] [Full Text] [PDF] V. Seaman, A. Jumaan, E. Yanni, B. Lewis, J. Neyer, P. Roda, M. Xu, and R. Hoffman Use of Molecular Testing to Identify a Cluster of Patients with Polycythemia Vera in Eastern Pennsylvania Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 534 - 540. [Abstract] [Full Text] [PDF] S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice Blood, May 15, 2008; 111(10): 5109 - 5117. [Abstract] [Full Text] [PDF] P. M. Mannucci and F. Peyvandi Thrombophilia Screening: Little Role for the JAK2V617F Mutation Mayo Clin. Proc., April 1, 2008; 83(4): 398 - 399. [Full Text] [PDF] M. A. Vickers JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation Blood, September 1, 2007; 110(5): 1675 - 1680. [Abstract] [Full Text] [PDF] Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth J. Biol. Chem., February 9, 2007; 282(6): 3428 - 3432. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020